PDT VS RFA FOR BARRETT'S OESOPHAGUS
HOW TO CHOOSE
Radiofrequency ablation has become the standard for Barrett's oesophagus ablation at most centres โ but PDT still has an important role. Understanding the honest strengths and weaknesses of each approach is essential for patients making informed decisions about pre-cancer management.
analyticsAt a Glance
- check_circleRFA is now the first-line standard for Barrett's HGD at most Western centres โ strong trial evidence
- check_circleRFA advantage: no systemic photosensitivity; lower stricture rate; outpatient-friendly
- check_circlePDT remains first choice when RFA fails, is unavailable, or for long-segment circumferential disease
- check_circleThe two treatments are often used in sequence โ PDT can rescue RFA failures and vice versa
Why This Comparison Matters
Barrett's oesophagus with high-grade dysplasia (HGD) โ pre-cancerous changes that progress to invasive oesophageal adenocarcinoma in 5โ10% of patients per year if untreated โ has two established endoscopic ablation options: PDT and RFA. The choice between them affects patient quality of life (primarily through photosensitivity), clearance rates, stricture risk, and access to retreatment if the first approach fails.
โRFA did not make PDT obsolete โ it became the preferred first option because it is more convenient for patients. PDT remains an essential part of the Barrett's treatment armamentarium, particularly for RFA failures and at centres where RFA systems are unavailable.โ
What Both Treatments Are Trying to Achieve
Both PDT and RFA aim to destroy the entire Barrett's mucosal segment โ including all areas of intestinal metaplasia and dysplasia โ replacing it with normal squamous epithelium that grows back on a healed normal oesophageal wall. "Complete eradication of intestinal metaplasia" (CE-IM) is the treatment endpoint, achieved when all Barrett's tissue is ablated and replaced by normal squamous mucosa on follow-up biopsy.
The Current Standard Recommendation
ACG (American College of Gastroenterology), BSG (British Society of Gastroenterology), and ESGE (European Society of Gastrointestinal Endoscopy) guidelines currently recommend RFA as the preferred ablation modality for Barrett's HGD and low-grade dysplasia. PDT is listed as an acceptable alternative and as the salvage option for RFA-refractory disease.
PDT vs RFA: Direct Comparison
A comprehensive head-to-head comparison across the most clinically relevant dimensions for Barrett's HGD patients.
RFA Advantages
- No Systemic PhotosensitivityRFA has zero photosensitivity โ patients resume normal life immediately after treatment. No sun avoidance, no light precautions.
- Lower Stricture RateRFA stricture rate 6โ12%; PDT stricture rate for circumferential treatment 20โ30%. RFA's controlled, uniform energy delivery produces less scarring.
- Outpatient FriendlyRFA is a single-session outpatient endoscopy โ no drug injection, no waiting period, no two-day hospital sequence.
- Stronger Current Evidence BaseAIM Dysplasia Trial (NEJM 2009): RFA achieved CE-IM in 77% vs 2% sham, CE-HGD 81% vs 19%. The landmark RCT for endoscopic Barrett's ablation.
- More Widely AvailableHALO360 and HALO90 RFA systems are more widely distributed than PDT laser systems at endoscopy centres globally.
PDT Advantages
- Established Longer Track RecordPDT for Barrett's HGD has been used since the mid-1990s โ the original published evidence base for endoscopic ablation of HGD.
- Effective for Very Long Segment DiseasePDT light delivery via a cylindrical diffuser can treat longer Barrett's segments in a single session than the HALO360 catheter length allows.
- Salvage for RFA FailuresFor patients with residual or recurrent HGD after RFA, PDT provides a different energy mechanism for retreatment โ the combination is more effective than either alone.
- Available at More Asian CentresAt centres in China, India, and other Asian countries, Photofrin PDT is more commonly available than RFA systems for oesophageal ablation.
- No Repeat Session RequiredA single Photofrin PDT course (one injection, one light delivery, one debridement) treats the full Barrett's segment; RFA typically requires 2โ3 sessions to achieve CE-IM.
Outcomes Comparison: Published Data
Key efficacy and safety outcomes from the major PDT and RFA studies for Barrett's HGD.
| Outcome | PDT (Photofrin) | RFA (HALO) | Clinical Note |
|---|---|---|---|
| Complete Eradication of HGD (CE-HGD) | 77โ87% | 81โ91% | Both achieve similar HGD eradication; RFA slightly higher in RCT conditions |
| Complete Eradication of IM (CE-IM) | 52โ60% | 74โ77% | RFA achieves higher complete IM eradication โ important for long-term cancer risk reduction |
| Oesophageal Stricture Rate | 20โ30% (circumferential) | 6โ12% | Largest practical difference: PDT stricture rate substantially higher |
| Photosensitivity Duration | 4โ6 weeks full body | None | RFA's decisive quality-of-life advantage |
| Sessions to CE-IM | 1โ2 sessions | 2โ4 sessions (circumferential + focal) | PDT fewer sessions; RFA better tolerated per session |
| Recurrence Rate at 5 Years | 30โ40% | 25โ35% | Comparable long-term recurrence; surveillance essential for both |
When PDT Is Still the Better Choice
Despite RFA's favoured status in guidelines, there are specific clinical scenarios where PDT remains the preferred or only option.
RFA Has Failed: Residual or Recurrent HGD
Approximately 15โ25% of patients treated with RFA have residual or recurrent HGD at follow-up endoscopy. For these "RFA-refractory" patients, PDT provides a different energy mechanism โ photochemical cell death rather than thermal ablation โ that can achieve eradication where RFA has not. PDT after RFA failure achieves CE-HGD in 60โ70% of treated patients.
Very Long Segment Barrett's (>8โ10 cm)
The HALO360 circumferential catheter treats approximately 3 cm per application. For very long Barrett's segments, multiple overlapping RFA applications are required โ substantially extending the number of sessions needed. A single PDT course using a cylindrical diffuser fibre covers much longer segments in one session, which may be more practical for extensive disease.
RFA Not Available at the Treating Centre
At centres in Asia, Eastern Europe, and developing countries, Photofrin PDT systems are available where RFA equipment has not been installed. For patients accessing treatment in these settings, PDT is the primary option โ and at experienced centres, it achieves outcomes comparable to RFA for the HGD indication.
Patient Preference After Informed Discussion
Some patients, when fully counselled about both options, prefer PDT's fewer sessions despite the photosensitivity requirement โ particularly those who have already had a Photofrin course and understand the precautions, or those for whom multiple endoscopy sessions are logistically difficult.
Sequential Approach: Using Both PDT and RFA
Many patients with Barrett's HGD ultimately receive both PDT and RFA โ often RFA first, then PDT for residual disease, or PDT first at centres where RFA is now available and RFA for focal recurrences.
RFA โ PDT Sequence (Most Common)
RFA as first-line treatment for Barrett's HGD. If residual or recurrent HGD is identified at follow-up, PDT (Photofrin) is added for complete eradication. Combined series show CE-HGD rates of 90โ95% with sequential RFA + PDT โ higher than either modality alone. This sequence exploits the different energy mechanisms of each treatment.
PDT โ RFA Sequence (Asian Centres)
At centres where PDT was established first and RFA was added later, or where RFA is only available for focal applications, PDT treats the long segment and RFA addresses focal residual lesions. This approach is common at experienced Asian centres building RFA capacity alongside existing PDT programmes.
Explore the PDT Knowledge Base
Related PDT and oesophageal topics.
Frequently Asked Questions
Common questions about choosing between PDT and RFA for Barrett's oesophagus.
About the Decision
My doctor recommends RFA. Should I ask about PDT as an alternative?
RFA is a well-founded first recommendation for Barrett's HGD and the current guideline standard. If you have concerns about the multiple sessions required for RFA or want to understand all options, asking about PDT is entirely reasonable. The most important question to ask is whether your centre has experience with both modalities โ a centre experienced in only one may not give a fully balanced assessment. At experienced endoscopy programmes, the conversation about RFA vs PDT is routine.
Can I have RFA if I previously had PDT that did not work?
Yes. RFA after PDT failure is used at experienced centres โ the thermal energy mechanism of RFA is entirely different from PDT's photochemical mechanism, and prior PDT does not create a contraindication to subsequent RFA. Similarly, PDT after RFA failure is well-documented and effective. Sequential use of both modalities in the same patient is standard practice at high-volume Barrett's programmes.
Access
Is RFA or PDT more available internationally?
RFA systems (HALO360/90) are more widely distributed at major endoscopy centres in the US, UK, Europe, and Japan. In Asia โ including China and India โ Photofrin PDT is often available at academic medical centres where RFA equipment has not yet been installed. If you are accessing treatment internationally, CancerFax identifies which modality is available at each centre and advises on the most appropriate option for your specific Barrett's disease extent and history.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Barrett's Oesophagus with HGD? We Can Help You Access the Right Treatment.
Upload your endoscopy reports, biopsy results, and prior treatment history. Our team will assess whether RFA, PDT, or a combination approach is appropriate and identify the best centre for your specific Barrett's disease.
For informational purposes only. Barrett's oesophagus management decisions require evaluation by qualified gastroenterology and GI oncology specialists.